Phase 1 N=27 Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine
Group B Streptococcus Infection
Primary: Treatment Emergent Adverse Events — 10; 7; 10; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=15 Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Prostate Cancer
Primary: Dose-dependent Toxicity — 0; 2; 0; 2 participants
Phase 1 N=8 A Study to Learn About the Study Medicine Called CTB+AVP in Healthy Adult People.
Healthy
Primary: Maximum Observed Concentration (Cmax) of Cis-Ceftibuten (CTB): Part 1 — 18170; 25470; 30510; 27120 Nanogram per milliliter (ng/mL)
Phase 1 N=33 Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans
Active Ethanol and Active Iomazenil · Active Ethanol and Placebo Iomazenil · Placebo Ethanol and Active Iomazenil
Primary: Biphasic Ethanol Effects Scale (BAES) — 3.767; 3.935; 3.813; 3.194 score on a scale
Phase 1 N=24 Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
Metastatic Carcinoma in the Liver · Resectable Mass · Stage IV Colorectal Cancer AJCC v7
Primary: Post-operative Toxicity — 8 Participants
Phase 1 N=12 A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)
Neoplasm
Primary: Part A: Number of Patients With Dose Limiting Toxicities (DLTs) in the MTD Evaluation Period — 1; 0; 2 Participants
Phase 1 N=28 A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
Pulmonary Disease · Tuberculosis, Pulmonary · Tuberculosis
Primary: TBAJ-876 Effect on the Pharmacokinetics of the CYP-3A4 Substrate Midazolam in Healthy Adult Subjects: Pharmacokinetic Parameters AUC — 22.64; 25.22; 24.28; 25.68 ng.hr/mL
Phase 1 N=14 A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
Healthy Participants
Primary: PF-07321332 Maximum Observed Plasma Concentration (Cmax) on Day 1 — 3082 nanograms per milliliter (ng/mL)
Phase 1 N=11 Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
Osteogenesis Imperfecta
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 2; 4; 2; 1 Participants
Phase 1 N=113 Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
Chronic Hepatitis B
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 4; 5; 4 Participants
Phase 1 N=15 A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
Alopecia Areata
Primary: Area Under the Plasma Concentration-Time Profile Over the Dosing Interval of 24 Hours, at Steady State (AUC24ss/AUCtau) of Ritlecitinib on Day 7 — 437.5 Nanogram*hours…
Phase 1 N=61 A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
Alzheimer Disease
Primary: Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr) — -0.050; -0.122; -0.183; -0.255 standard uptake value…
Phase 1 N=63 A Study of LY3002813 in Participants With Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 1; 0; 2; 0 Participants
Phase 1 N=39 Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects
Healthy
Primary: The Occurrence of Serious Adverse Events (SAE) Following Administration of G03-52-01 to the Final Follow-up Visit. — 0; 0; 0; 0 Number of SAEs
Phase 1 N=8 Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma
High-risk Neuroblastoma
Primary: Number of Participants With Adverse Events (AEs) — 8; 1 Participants